Earnings summaries and quarterly performance for AN2 Therapeutics.
Executive leadership at AN2 Therapeutics.
Board of directors at AN2 Therapeutics.
Research analysts covering AN2 Therapeutics.
Recent press releases and 8-K filings for ANTX.
AN2 Therapeutics Provides Strategic Update and Pipeline Outlook
ANTX
New Projects/Investments
Guidance Update
- AN2 Therapeutics underwent a significant transition in 2025 after its lead compound, epetraborole, did not show the expected signal in a Phase 3 trial for nontuberculous mycobacteria lung disease.
- The company is now focused on advancing two oncology programs (ENPP1 and PI3K alpha inhibitors) expected to enter the clinic within six to nine months, and a novel compound for Chagas disease currently in Phase 1.
- ANTX is also pursuing an investigator-initiated trial for epetraborole in Mycobacterium abscessus, targeting a $1 billion-plus U.S. market and aiming for Phase 3 enablement.
- AN2 Therapeutics projects a cash runway into early 2028 and is leveraging non-dilutive funding and partnerships to support its pipeline.
Dec 3, 2025, 3:50 PM
ANTX Provides Pipeline Update and 2026 Outlook
ANTX
New Projects/Investments
Guidance Update
- AN2 Therapeutics (ANTX) reported a cash runway into early 2028.
- The company is advancing two oncology programs, an ENPP1 inhibitor and a PI3K alpha inhibitor, with preclinical data showing strong profiles and an expectation to enter the clinic within 6 to 9 months.
- In infectious diseases, ANTX is initiating a 90-patient investigator-initiated trial for Mycobacterium abscessus and is well into Phase 1 for its Chagas disease program, with plans to initiate Phase 2.
- Key milestones for 2026 include the start and enrollment of the abscessus trial, completion of Chagas Phase 1 and initiation of Phase 2, and the two cancer programs entering development.
Dec 3, 2025, 3:50 PM
AN2 Therapeutics Reports Q3 2025 Financial Results and Pipeline Progress
ANTX
Earnings
New Projects/Investments
- AN2 Therapeutics reported a net loss of $9.4 million for the third quarter ended September 30, 2025, an improvement from $12.7 million in the same period of 2024.
- The company held $65.1 million in cash, cash equivalents, and investments as of September 30, 2025, which is projected to fund operations into 2028.
- Key pipeline advancements include anticipated Phase 1 data in Q1 2026 for the Chagas disease program (AN2-502998) and the planned entry of the first oncology compound into development in early 2026.
- AN2 also announced a research collaboration with GSK for tuberculosis therapies, supported by a third year of funding from the Gates Foundation.
Nov 12, 2025, 9:19 PM
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
ANTX
Earnings
New Projects/Investments
- AN2 Therapeutics reported a net loss of $9.4 million for the third quarter of 2025, compared to a $12.7 million net loss for the same period in 2024.
- The company ended Q3 2025 with $65.1 million in cash, cash equivalents, and investments, projecting this will sustain operations into 2028.
- The oral AN2-502998 for Chagas disease is progressing through a Phase 1 clinical trial, with data anticipated in Q1 2026 and Phase 2 planning underway.
- The first of two boron-based oncology targets is expected to enter development in early 2026, and an investigator-initiated trial for the M. abscessus program is expected to begin enrollment in early 2026.
- AN2 Therapeutics announced a research collaboration with GSK to advance boron-based LeuRS-inhibitors targeting tuberculosis, supported by a third year of funding from the Gates Foundation.
Nov 12, 2025, 9:01 PM
AN2 Therapeutics Announces Research Collaboration with GSK for Tuberculosis Therapies
ANTX
New Projects/Investments
- AN2 Therapeutics has announced a research collaboration with GSK to advance boron-based LeuRS-inhibitors targeting tuberculosis (TB).
- The Gates Foundation will provide a third year of funding to support AN2's work within this collaboration.
- This partnership aims to address the global health challenge of TB, which causes over 1.25 million deaths annually.
Nov 10, 2025, 12:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more